Paul R Hutson
Overview
Explore the profile of Paul R Hutson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicholas C, Horton D, Malicki J, Baltes A, Hutson P, Brown R
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(4):253-261.
PMID: 40046866
Background: Psilocybin has demonstrated promising clinical outcomes for nicotine and alcohol use disorders, yet its potential clinical utility in the treatment of opioid use disorder (OUD) remains unreported in modern...
2.
Nicholas C, Banks M, Lennertz R, Wenthur C, Krause B, Riedner B, et al.
Transl Psychiatry
. 2024 Sep;
14(1):372.
PMID: 39266503
Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and improved well-being in healthy participants, but whether these therapeutic effects are...
3.
Volk C, Hutson P, Rose W
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae315.
PMID: 38938895
Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic that is increasingly utilized for infections that require prolonged treatment durations despite the lack of Food and Drug Administration approval for these indications....
4.
Jenkins A, Scarlett C, Beames T, Rivera-Gonzalez K, Martin A, Sun M, et al.
Toxicol Rep
. 2023 Oct;
11:310-317.
PMID: 37789951
Piperonyl butoxide (PBO) is a popular insecticide synergist present in thousands of commercial, agricultural, and household products. PBO inhibits cytochrome P450 activity, impairing the ability of insects to detoxify insecticides....
5.
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, et al.
JAMA
. 2023 Aug;
330(9):843-853.
PMID: 37651119
Importance: Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of...
6.
Peh K, Przybylski D, Fallon M, Bergsbaken J, Hutson P, Yu M, et al.
J Oncol Pharm Pract
. 2022 Apr;
29(5):1094-1102.
PMID: 35369813
Purpose: Molecular tumor boards provide precision treatment recommendations based on cancer genomic profile. However, practical barriers limit their benefits. We studied the clinical utility of the precision medicine molecular tumor...
7.
Bishop M, Hutson P, Hank J, Sondel P, Furman W, Meagher M, et al.
MAbs
. 2020 Jul;
12(1):1773751.
PMID: 32643524
Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m daily for 4 days in...
8.
Rose W, Hutson P
Drugs Real World Outcomes
. 2020 Jun;
7(Suppl 1):36-40.
PMID: 32588386
Background: Antibiotics for the treatment of complicated, multidrug-resistant Gram-positive infections are limited, especially when prolonged treatment is necessary. Oritavancin is approved for the treatment of serious skin infections as a...
9.
Dahmane E, Hutson P, Gobburu J
Clin Pharmacol Drug Dev
. 2020 Apr;
10(1):78-85.
PMID: 32250059
Psilocybin is being developed for treating major depressive disorder. Psilocybin is readily dephosphorylated to psilocin upon absorption. The potential for psilocin proarrhythmic effect was assessed using a concentration-QTc interval (C-QTc)...
10.
Goldberg S, Pace B, Nicholas C, Raison C, Hutson P
Psychiatry Res
. 2020 Jan;
284:112749.
PMID: 31931272
The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled;...